Despite the high response rate to PD-1/PD-L1 blockade, in the end, around half of MCC patients do not derive durable benefit from therapy, and no strong alternative therapeutic strategy for this cohort currently exists. The gene discussed is CD274; the disease is Merkel cell skin cancer.